GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codexis Inc (LTS:0I0X) » Definitions » Institutional Ownership

Codexis (LTS:0I0X) Institutional Ownership : 40.16% (As of Apr. 18, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Codexis Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Codexis's institutional ownership is 40.16%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Codexis's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Codexis's Float Percentage Of Total Shares Outstanding is 89.65%.


Codexis Institutional Ownership Historical Data

The historical data trend for Codexis's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codexis Institutional Ownership Chart

Codexis Historical Data

The historical data trend for Codexis can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 44.50 43.07 43.01 36.46 36.25 36.60 39.01 40.33 40.06 40.16

Codexis Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Codexis Business Description

Traded in Other Exchanges
Address
200 Penobscot Drive, Redwood City, CA, USA, 94063
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Codexis Headlines

No Headlines